Show simple item record

dc.contributor.authorSchumacher, F-R
dc.contributor.authorSiew, K
dc.contributor.authorZhang, J
dc.contributor.authorJohnson, C
dc.contributor.authorWood, N
dc.contributor.authorCleary, SE
dc.contributor.authorAl Maskari, RS
dc.contributor.authorFerryman, JT
dc.contributor.authorHardege, I
dc.contributor.authorYasmin
dc.contributor.authorFigg, NL
dc.contributor.authorEnchev, R
dc.contributor.authorKnebel, A
dc.contributor.authorO'Shaughnessy, KM
dc.contributor.authorKurz, T
dc.date.accessioned2018-07-09T14:27:54Z
dc.date.issued2015-10-01
dc.description.abstractDeletion of exon 9 from Cullin‐3 (CUL3, residues 403–459: CUL3Δ403–459) causes pseudohypoaldosteronism type IIE (PHA2E), a severe form of familial hyperkalaemia and hypertension (FHHt). CUL3 binds the RING protein RBX1 and various substrate adaptors to form Cullin‐RING‐ubiquitin‐ligase complexes. Bound to KLHL3, CUL3‐RBX1 ubiquitylates WNK kinases, promoting their ubiquitin‐mediated proteasomal degradation. Since WNK kinases activate Na/Cl co‐transporters to promote salt retention, CUL3 regulates blood pressure. Mutations in both KLHL3 and WNK kinases cause PHA2 by disrupting Cullin‐RING‐ligase formation. We report here that the PHA2E mutant, CUL3Δ403–459, is severely compromised in its ability to ubiquitylate WNKs, possibly due to altered structural flexibility. Instead, CUL3Δ403–459 auto‐ubiquitylates and loses interaction with two important Cullin regulators: the COP9‐signalosome and CAND1. A novel knock‐in mouse model of CUL3WT/Δ403–459 closely recapitulates the human PHA2E phenotype. These mice also show changes in the arterial pulse waveform, suggesting a vascular contribution to their hypertension not reported in previous FHHt models. These findings may explain the severity of the FHHt phenotype caused by CUL3 mutations compared to those reported in KLHL3 or WNK kinases.en_GB
dc.description.sponsorshipThis work was supported by the British Heart Foundation (a PhD studentship to KS and PG 13 89 30577), Medical Research Council, and an ERC Starting Investigator Grant (to TK), as well as the pharmaceutical companies supporting the Division of Signal Transduction Therapy Unit (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Janssen Pharmaceutica and Pfizer). The Human Research Tissue Bank is supported by the NIHR Cambridge Biomedical Research Centre.en_GB
dc.identifier.citationVol. 7, pp. 1285 - 1306en_GB
dc.identifier.doi10.15252/emmm.201505444
dc.identifier.urihttp://hdl.handle.net/10871/33416
dc.language.isoenen_GB
dc.publisherWileyen_GB
dc.rights© 2015 The Authors. Published under the terms of the CC BY 4.0 license License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en_GB
dc.subjectcullinen_GB
dc.subjectCUL3en_GB
dc.subjectmonogenic hypertension syndromesen_GB
dc.subjectproteasomeen_GB
dc.subjectubiquitinen_GB
dc.subjectWNK/SPAK/OSR1 pathwayen_GB
dc.titleCharacterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemiaen_GB
dc.typeArticleen_GB
dc.date.available2018-07-09T14:27:54Z
dc.identifier.issn1757-4676
dc.descriptionThis is the final version of the article. Available from the publisher via the DOI in this record.en_GB
dc.identifier.journalEMBO Molecular Medicineen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record